KBC Group
NKTR icon

KBC Group’s Nektar Therapeutics NKTR Stock Holding History

KBC Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$71K Hold
1,167
– – ﹤0.01% 1594
2026
Q2 		$81K Buy
1,167
+446
+62% +$32.6K ﹤0.01% 1524
2026
Q1 		$52K Buy
+721
New +$41.1K ﹤0.01% 1634
2023
Q2 		– Sell
-1,082
Closed -$11K – 1507
2023
Q1 		$11K Hold
1,082
– – ﹤0.01% 1497
2022
Q4 		$37K Hold
1,082
– – ﹤0.01% 1451
2022
Q3 		$52K Hold
1,082
– – ﹤0.01% 1385
2022
Q2 		$62K Buy
1,082
+465
+75% +$29.3K ﹤0.01% 1380
2022
Q1 		$50K Buy
617
+46
+8% +$6.81K ﹤0.01% 1243
2021
Q4 		$116K Buy
571
+84
+17% +$18.2K ﹤0.01% 1155
2021
Q3 		$131K Hold
487
– – ﹤0.01% 1129
2021
Q2 		$125K Hold
487
– – ﹤0.01% 1145
2021
Q1 		$146K Hold
487
– – ﹤0.01% 1136
2020
Q4 		$124K Buy
487
+117
+32% +$30.2K ﹤0.01% 1132
2020
Q3 		$92K Sell
370
-4,750
-93% -$1.49M ﹤0.01% 1128
2020
Q2 		$1.78M Sell
5,120
-18,782
-79% -$5.86M 0.01% 581
2020
Q1 		$6.4M Sell
23,902
-7,072
-23% -$2.19M 0.05% 325
2019
Q4 		$10M Buy
30,974
+28,290
+1,054% +$8.2M 0.06% 322
2019
Q3 		$733K Buy
2,684
+1,691
+170% +$620K 0.01% 977
2019
Q2 		$530K Hold
993
– – ﹤0.01% 1051
2019
Q1 		$500K Buy
993
+198
+25% +$117K ﹤0.01% 1082
2018
Q4 		$392K Buy
795
+19
+2% +$11.5K ﹤0.01% 981
2018
Q3 		$710K Hold
776
– – 0.01% 1019
2018
Q2 		$569K Buy
+776
New +$895K ﹤0.01% 955
2018
Q1 		– Sell
-1,648
Closed -$1.48M – 1304
2017
Q4 		$1.48M Buy
+1,648
New +$975K 0.01% 669
2016
Q4 		– Sell
-3,161
Closed -$815K – 1323
2016
Q3 		$815K Buy
3,161
+1,700
+116% +$438K 0.01% 831
2016
Q2 		$312K Buy
+1,461
New +$327K ﹤0.01% 985

Other funds holding NKTR

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
LVW Advisors
LVW Advisors Pittsford, New York $1.19B AUM 19.73% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Activest Wealth Management
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

KBC Group's NKTR Position: Q3 2026 in Review

KBC Group held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 1,167 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

KBC Group first reported a position in NKTR in Q2 2016 and has held it in 26 quarters since. The position peaked at $10M in Q4 2019. 20 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • KBC Group held 1,167 shares of Nektar Therapeutics worth $71K as of Q3 2026.
  • KBC Group left its Nektar Therapeutics share count unchanged in Q3 2026.
  • Nektar Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1594 holding.
  • KBC Group first reported a position in Nektar Therapeutics in Q2 2016 and has held it in 26 quarters since.
  • KBC Group's Nektar Therapeutics position peaked at $10M in Q4 2019.
  • 20 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.